References

  1. Bushby K, Bourke J, Quinby J, et al. The multidisciplinary management of Duchenne muscular dystrophy. Current Paediatrics 2005;15: 292-300.
  2. Finder JD, Birnkrant D, Carl J, et al. Respiratory care of the patient with Duchenne muscular dystrophy:ATS consensus statement. Am J Respir Crit Care Med. 2004:170(4): 456-65.
  3. Bushby K, Muntoni F, Griggs R, et al. Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids 2-4 April 2004, Naarden, The Netherlands. Neuromusc Disord 2004;14: 526-534.
  4. Eagle M, Baudouin SV, Bushby K, et al. Survival in Duchenne Muscular Dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromusc Disord 2002;12(10):926-9.
  5. Simmonds AK, Muntoni F, Fielding 5, et al. Impact of nasal ventilation on survival in hypercapnic Duchenne Muscular Dystrophy. Thorax 1998;53: 949-53.
  6. Smith PE, Edwards RH, Calverley PM. Oxygen treatment of sleep hypoxaernia in Duchenne muscular dystrophy. Thorax 1989; 44: 997-1001.
  7. Bushby KMD, Muntoni F, Bourke JP. The management of cardiac complications in muscular dystrophy and myotonic dystrophy. Proceedings of the 107th ENMC Workshop. Neuromusc Disord 2003;13: 166-72.
  8. Chenard, A. A., Becane H. M., et al. 'Ventricular arrhythmia in Duchenne muscular dystrophy: Prevalence, significance and prognosis.' Neuromuscular Disorders 1993;3(3): 201-206.
  9. Yotsukura M, Fujii K, Katayama A, et al. Nine-year follow-up study of heart rate variability in patients with Duchenne-type progressive muscular dystrophy. Am Heart J. 1998;136: 289-296.
  10. Quinlivan R, Roper H, Bushby K, et al. Report of a muscular dystrophy campaign funded workshop Birmingham, UK, January 16th 2004. Osteoporosis in Duchenne muscular dystrophy; its prevalence, treatment and prevention. Neuromuscul Disord 2005;15(1): 72-9.
  11. Larson CM, Henderson RC. Bone mineral density and fractures in patients with Duchenne Muscular Dystrophy following deflazacort, Neuromusc Disord 2002;12: 294-5.
  12. McDonald DGM, Kinali M, Gallagher AC, et al. Fracture prevalence in Duchenne muscular dystrophy. Dev Med Child Neural 2002;44: 695-698.
  13. Hayes J, Veyckemans F, Bissonnette B. Duchenne muscular dystrophy: an old anesthesia problem revisited. Pediatr Anesth 2008;18: 100-106.
  14. Yemen TA, McClain C. Muscular dystrophy, anesthesia and the safety of inhalational agents revisited, again. Paediak Anaesth 2006;16: 105-108,
  15. Birnkrant DJ, Panitch HB, Benditt JO, et al. American College of Chest Physicians consensus statement on the respiratory and related management of patients with Duchenne muscular dystrophy undergoing anesthesia or sedation. Chest 2007; 132: 1977-1986.
  16. Keifer A, Singer W, Reynold R. Malignant Hypertherrnia in a child with Duchenne Muscular Dystrophy. Paediatrics 1983; 71: 118-119.

Websites

www.actionduchenne.org

www.duchenneuk.org

www.muscular-dystrophy.org

www.treat.nmd.eu